Literature DB >> 12071638

Argyrophilic grain disease is a sporadic 4-repeat tauopathy.

Takashi Togo1, Naruhiko Sahara, Shu-Hui Yen, Natalie Cookson, Takashi Ishizawa, Mike Hutton, Rohan de Silva, Andrew Lees, Dennis W Dickson.   

Abstract

Argyrophilic grain disease (AGD) was first reported as an adult-onset dementia, but recent studies have emphasized personality change, emotional imbalance, and memory problems as clinical features of AGD. AGD is characterized by spindle- or comma-shaped argyrophilic grains in the neuropil of entorhinal cortex, hippocampus, and amygdala. Immunohistochemistry with monoclonal antibodies specific to tau isoforms with four (4R) or three (3R) repeats in the microtubule-binding domain showed immunostaining of grains with 4R, but not 3R, tau antibodies, suggesting that AGD was a 4R tauopathy. The tau isoform composition of AGD was confirmed with densitometric analysis of Western blots of sarkosyl-insoluble tau from the medial temporal lobe of AGD brains with a range of concurrent neurofibrillary pathology and compared with Alzheimer controls. The 4R/3R ratio was 1 or less for Alzheimer disease; the 4R/3R ratio was more than 1 for AGD, decreasing with increasing neurofibrillary pathology and demonstrating that insoluble tau in AGD was enriched in 4R tau. The frequency of the extended tau haplotype was not different in AGD compared to other sporadic 4R tauopathies, progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD). Furthermore, AGD occurred in PSP and CBD more frequently than in dementia controls, including Alzheimer disease. These results suggest that AGD, PSP and CBD are 4R tauopathies that share common pathologic, biochemical, and genetic characteristics.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12071638     DOI: 10.1093/jnen/61.6.547

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  64 in total

Review 1.  Current Understanding of Neurodegenerative Diseases Associated With the Protein Tau.

Authors:  Keith A Josephs
Journal:  Mayo Clin Proc       Date:  2017-08       Impact factor: 7.616

2.  Autopsy consent, brain collection, and standardized neuropathologic assessment of ADNI participants: the essential role of the neuropathology core.

Authors:  Nigel J Cairns; Lisa Taylor-Reinwald; John C Morris
Journal:  Alzheimers Dement       Date:  2010-05       Impact factor: 21.566

3.  A novel tau mutation, p.K317N, causes globular glial tauopathy.

Authors:  Pawel Tacik; Michael DeTure; Wen-Lang Lin; Monica Sanchez Contreras; Aleksandra Wojtas; Kelly M Hinkle; Shinsuke Fujioka; Matthew C Baker; Ronald L Walton; Yari Carlomagno; Patricia H Brown; Audrey J Strongosky; Naomi Kouri; Melissa E Murray; Leonard Petrucelli; Keith A Josephs; Rosa Rademakers; Owen A Ross; Zbigniew K Wszolek; Dennis W Dickson
Journal:  Acta Neuropathol       Date:  2015-04-22       Impact factor: 17.088

4.  Complex proteinopathy with accumulations of prion protein, hyperphosphorylated tau, α-synuclein and ubiquitin in experimental bovine spongiform encephalopathy of monkeys.

Authors:  Pedro Piccardo; Juraj Cervenak; Ming Bu; Lindsay Miller; David M Asher
Journal:  J Gen Virol       Date:  2014-04-25       Impact factor: 3.891

5.  Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study.

Authors:  Melissa E Murray; Neill R Graff-Radford; Owen A Ross; Ronald C Petersen; Ranjan Duara; Dennis W Dickson
Journal:  Lancet Neurol       Date:  2011-07-27       Impact factor: 44.182

6.  Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration.

Authors:  Nigel J Cairns; Eileen H Bigio; Ian R A Mackenzie; Manuela Neumann; Virginia M-Y Lee; Kimmo J Hatanpaa; Charles L White; Julie A Schneider; Lea Tenenholz Grinberg; Glenda Halliday; Charles Duyckaerts; James S Lowe; Ida E Holm; Markus Tolnay; Koichi Okamoto; Hideaki Yokoo; Shigeo Murayama; John Woulfe; David G Munoz; Dennis W Dickson; Paul G Ince; John Q Trojanowski; David M A Mann
Journal:  Acta Neuropathol       Date:  2007-06-20       Impact factor: 17.088

7.  Prominent psychiatric symptoms in patients with Parkinson's disease and concomitant argyrophilic grain disease.

Authors:  O Grau-Rivera; E Gelpi; M J Rey; F Valldeoriola; E Tolosa; Y Compta; M J Martí
Journal:  J Neurol       Date:  2013-09-18       Impact factor: 4.849

Review 8.  Challenges and new opportunities in the investigation of new drug therapies to treat frontotemporal dementia.

Authors:  Edward D Huey; Nicole Armstrong; Parastoo Momeni; Jordan Grafman
Journal:  Expert Opin Ther Targets       Date:  2008-11       Impact factor: 6.902

Review 9.  Hippocampal Sclerosis, Argyrophilic Grain Disease, and Primary Age-Related Tauopathy.

Authors:  Gregory A Jicha; Peter T Nelson
Journal:  Continuum (Minneap Minn)       Date:  2019-02

10.  Linkage disequilibrium and association of MAPT H1 in Parkinson disease.

Authors:  Lisa Skipper; Kristen Wilkes; Mathias Toft; Matthew Baker; Sarah Lincoln; Mary Hulihan; Owen A Ross; Mike Hutton; Jan Aasly; Matthew Farrer
Journal:  Am J Hum Genet       Date:  2004-08-03       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.